Gesynta Pharma’s drug candidates show potential in a range of diseases

Gesynta Pharma is a Swedish pharmaceutical company that develops unique drug candidates with the aim to reduce harmful inflammation and increase blood flow in the body’s microvasculature, thereby providing safe and efficacious treatments for several serious diseases. In a short time, Gesynta Pharma’s strong management team and renowned board of directors have combined excellence in research and development with suave entrepreneurship to build a robust scientific platform and clinical pipeline. With a portfolio of drug candidates with the unique capability to reduce inflammation and protect blood vessels, Gesynta Pharma stands well prepared for its continued value creation.
Read more about our development projects
Experienced team with excellent track record
  • Board members and management of Gesynta Pharma have extensive experience from leading positions in major pharmaceutical companies, as well as deep knowledge about all phases of drug development from discovery to the commercialization of approved products.
  • The company has presented positive study outcomes and generated a robust financial foundation for its continued value creation activities.
A strong investor base
  • Gesynta Pharma has a solid financial situation. Owners include reputable institutional investors such as Industrifonden, Linc, and Hadean Ventures, as well as several successful life science industry entrepreneurs.
A solid clinical pipeline based on drug candidates with a unique mode of action
  • Gesynta Pharma’s drug candidates target both rare diseases as well as major diseases with large patient populations.
  • The high unmet medical needs addressed by the company’s drug candidates imply significant commercial potential on the global market.
Lead compound GS-248 in Phase II for systemic sclerosis
  • In preclinical studies, the lead drug candidate GS-248 has shown a unique ability to reduce inflammation while simultaneously dilating the body's smallest vessels. These properties may lead to improved treatments for a number of serious diseases.
  • GS-248 is currently being developed as a new treatment for the rare disease systemic sclerosis. GS-248 has been granted Orphan Drug Designation in the US by the FDA for the treatment of systemic sclerosis.
Second-generation drug candidates with the potential to address other complex diseases
  • Gesynta Pharma’s next generation of pharmacological treatments present a broad range of opportunities based on unique anti-inflammatory, vasoprotective, and pain-relieving properties.
  • The first compound in this next generation series, GS-073, is expected to enter clinical phase I in 2022

To reach Gesynta Pharma, please visit Contact.

Learn more about Gesynta Pharma

Gesynta Pharma bases its R&D on groundbreaking research from the Karolinska Institutet.

Our executive team and board of directors hold vast experience in drug development, commercialization and company scale-up.

Systemic sclerosis is an autoimmune disease hallmarked by chronic inflammation in the body’s smallest blood vessels.

Raynaud’s phenomenon affects most systemic sclerosis patients. It is often the first sign of the disease.

Half of systemic sclerosis patients develop difficult-to-heal digital ulcers, hampering many everyday activities.

Our lead drug candidate GS-248 is currently under evaluation in a phase 2 study.